Search - tctmd.com

Displaying 1 - 20 of 193

Sort: Relevancy | Date

Carotid Revascularization Doesn’t Improve Cognition CREST-2

News Conference News ISC 2026

Carotid Revascularization Doesn’t Improve Cognition: CREST-2

February 04, 2026

PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats

News Conference News TCT 2025

PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats

October 28, 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

News Conference News ESC 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

September 05, 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

March 10, 2025

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

November 11, 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

OCT-Based Strategy Outperforms Angiography in Calcified Lesions: CALIPSO

News Conference News EuroPCR 2024

OCT-Based Strategy Outperforms Angiography in Calcified Lesions: CALIPSO

May 16, 2024

Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

News Conference News EuroPCR 2024

NOW PUBLISHED - Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

Michael O'Riordan

May 14, 2024

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

News Conference News ACC 2024

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

April 10, 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

News Conference News CRT 2024

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

March 09, 2024

Will IVUS Ever Take Off in Peripheral Vascular Interventions?

News Conference News ISET 2024

Will IVUS Ever Take Off in Peripheral Vascular Interventions?

January 31, 2024

Venous Stents: How to Choose Among the Wealth of Options

News Conference News ISET 2024

Venous Stents: How to Choose Among the Wealth of Options

January 26, 2024

Tack Works Well in Dissection Repair of Complex Lesions: TOBA II BTK

News Conference News ISET 2024

Tack Works Well in Dissection Repair of Complex Lesions: TOBA II BTK

January 25, 2024

Intermittent Coronary Sinus Occlusion Fails to Cut Infarct Size in STEMI

News Conference News TCT 2023

Intermittent Coronary Sinus Occlusion Fails to Cut Infarct Size in STEMI

Yael L. Maxwell

November 06, 2023

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

News Conference News TCT 2023

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

November 02, 2023

PARTHENOPE Adds to Polymer-Free Stent Data, But Raises ST Questions

News Conference News TCT 2023

PARTHENOPE Adds to Polymer-Free Stent Data, But Raises ST Questions

October 31, 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

October 25, 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

October 24, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.